These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26165039)

  • 1. [Breast cancer--selected aspects of systemic treatment].
    Pieńkowski T
    Pol J Pathol; 2014 Dec; 65(4 Suppl 2):S1-8. PubMed ID: 26165039
    [No Abstract]   [Full Text] [Related]  

  • 2. Hints of future progress for HER-2 breast cancer.
    Twombly R
    J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.
    Del Mastro L; Cazzaniga M; Solidoro P; Generali D; Bianchi G; Testore F; De Placido S
    Future Oncol; 2015; 11(16):2251-4. PubMed ID: 26260802
    [No Abstract]   [Full Text] [Related]  

  • 5. [Practice and consideration on neoadjuvant therapy for early breast cancer].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

  • 7. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular subtypes and individualized treatment of breast cancer].
    Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
    [No Abstract]   [Full Text] [Related]  

  • 9. New research on the treatment of small HER2-positive breast cancers.
    Krop IE
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].
    Hirano A; Shimizu T; Kamimura M; Ogura K; Kim N; Setoguchi Y; Okubo F; Kinoshita J; Ogawa K; Fujibayashi M
    Gan To Kagaku Ryoho; 2011 May; 38(5):771-6. PubMed ID: 21566435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P; Xu BH; Ma F; Li Q
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful endocrine therapy for locally advanced mucinous carcinoma of the breast.
    Nakagawa T; Sato K; Moriwaki M; Wada R; Arakawa A; Saito M; Kasumi F
    Breast J; 2012; 18(6):632-3. PubMed ID: 23110390
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple-negative breast cancer: a short review.
    Elias AD
    Am J Clin Oncol; 2010 Dec; 33(6):637-45. PubMed ID: 20023571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating the HER2 pathway in early and advanced breast cancer.
    Pegram MD
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.